NAMBAWAN Biotech has announced that the United States’ Patent and Trademark Office (USPTO) has issued the «Notice of Allowance» for the NOMAD’s patent application “Bacteriocins for control of Salmonella enterica”, U.S. Appl. No. 17/480,283. This is the second issued U.S. patent that protects NOMAD’s bacteriocins for control of Salmonella, non-antibiotic antibacterial biologics and the company’s lead product candidates for medicine, veterinary as well as food/feed safety markets. 

Concurrently, the Patent Office of India has issued the «Notice of Allowance» for the NOMAD’s patent application “Bacteriocins for control of Salmonella enterica”, Appl. No. IN201947037738. 

NOMAD is developing bacteriocins primarily as medical alternatives to antibiotics. The exclusive commercial license for non-medical use of NOMAD bacteriocins such as food, feed and veterinary, belongs to NAMBAWAN Biotech.

Salmonella enterica contaminating food products is the main cause of deaths due to bacterial enteric infections in USA and worldwide. Product candidates described and claimed in the patent are one or more Salmocins applied at very low doses; the products are highly and broadly active against all major pathogenic Salmonella strains causing food poisoning and clinical infections. We are aggressively filing for patent protection of all our inventions related to bacteriocins as precision biologics to be used as medicines and food/feed additives and food processing aids.

Currently, NOMAD/NAMBAWAN have patent protection for Salmonella Bacteriocins in USA (two patents), Australia, Japan and India, with applications in a number of countries pending.

About NAMBAWAN Biotech. NAMBAWAN Biotech GmbH is a NOMAD’s spin-off company that is the exclusive licensor of all NOMAD products, technologies and assets for the markets outside medicine. NAMBAWAN Biotech’s mission is to industrialize and commercialize NOMAD’s food additives – sweet tasting proteins for sweetener and taste modifier market and antimicrobial proteins for food and feed safety. NAMBAWAN’s wholly owned subsidiary NAMBAWAN Spain currently is at a pre-industrial phase and plans to start manufacturing and selling its lead product Thaumatin II starting 2025. Corporate office of NAMBAWAN Biotech is in Munich, Germany.

About NOMAD Bioscience GmbH. NOMAD Bioscience GmbH is a plant biotechnology company developing a broad range of biotechnology products manufactured in plants. Among the product candidates in development are antiviral proteins for prevention of respiratory viruses including influenza and corona viruses, non-antibiotic antimicrobials (bacterial bacteriocins and phage endolysins) for food safety and medicine, as well as natural high intensity non-caloric sweetener proteins thaumatins and brazzeins as sweeteners and taste modifiers. Corporate office of NOMAD Bioscience is in Munich, Germany.